Studies of serum-free culture medium in the generation of lymphokine activated killer cells

Linda Mesler Muul, Kathryn Nason-Burchenal, Cornelia Hyatt, Susan Schwarz, Dale Slavin, Elaine P. Director, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Lymphokine activated killer (LAK) cells administered in conjunction with recombinant interleukin-2 can mediate the regression of metastatic tumor in some patients with advanced cancer. In these trials LAK cells were activated in medium containing 2% human type A or AB serum. We have found three commercially available, serum-free culture media which allow development of in vitro LAK activity by human peripheral blood lymphocytes. They are AIMV (Gibco), MASF-3 (Whitaker-MA Bioproducts) and HB-104 (Dupont). If 2-mercaptoethanol was added to these culture media they were also capable of generating murine LAK cells which were effective in reducing pulmonary metastases in the murine MCA-106 model. Although LAK cells generated in these media have not been tested in humans yet, potentially they could provide a safe, unlimited and less expensive source of culture fluid for generating the large numbers of LAK cells needed for human clinical trials.

Original languageEnglish (US)
Pages (from-to)183-192
Number of pages10
JournalJournal of Immunological Methods
Volume105
Issue number2
DOIs
StatePublished - Dec 24 1987
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Serum-Free Culture Media
Mercaptoethanol
Lymphokines
Human Activities
Interleukin-2
Culture Media
Neoplasms
Clinical Trials
Lymphocytes
Neoplasm Metastasis
Lung
Serum

Keywords

  • Immunotherapy, adoptive
  • Interleukin-2, recombinant
  • Lymphokine-activated killer cell
  • Serum-free culture medium

ASJC Scopus subject areas

  • Biotechnology
  • Immunology

Cite this

Mesler Muul, L., Nason-Burchenal, K., Hyatt, C., Schwarz, S., Slavin, D., Director, E. P., & Rosenberg, S. A. (1987). Studies of serum-free culture medium in the generation of lymphokine activated killer cells. Journal of Immunological Methods, 105(2), 183-192. https://doi.org/10.1016/0022-1759(87)90265-1

Studies of serum-free culture medium in the generation of lymphokine activated killer cells. / Mesler Muul, Linda; Nason-Burchenal, Kathryn; Hyatt, Cornelia; Schwarz, Susan; Slavin, Dale; Director, Elaine P.; Rosenberg, Steven A.

In: Journal of Immunological Methods, Vol. 105, No. 2, 24.12.1987, p. 183-192.

Research output: Contribution to journalArticle

Mesler Muul, L, Nason-Burchenal, K, Hyatt, C, Schwarz, S, Slavin, D, Director, EP & Rosenberg, SA 1987, 'Studies of serum-free culture medium in the generation of lymphokine activated killer cells', Journal of Immunological Methods, vol. 105, no. 2, pp. 183-192. https://doi.org/10.1016/0022-1759(87)90265-1
Mesler Muul L, Nason-Burchenal K, Hyatt C, Schwarz S, Slavin D, Director EP et al. Studies of serum-free culture medium in the generation of lymphokine activated killer cells. Journal of Immunological Methods. 1987 Dec 24;105(2):183-192. https://doi.org/10.1016/0022-1759(87)90265-1
Mesler Muul, Linda ; Nason-Burchenal, Kathryn ; Hyatt, Cornelia ; Schwarz, Susan ; Slavin, Dale ; Director, Elaine P. ; Rosenberg, Steven A. / Studies of serum-free culture medium in the generation of lymphokine activated killer cells. In: Journal of Immunological Methods. 1987 ; Vol. 105, No. 2. pp. 183-192.
@article{9f00bf76692a42f48fa738c3377878d4,
title = "Studies of serum-free culture medium in the generation of lymphokine activated killer cells",
abstract = "Lymphokine activated killer (LAK) cells administered in conjunction with recombinant interleukin-2 can mediate the regression of metastatic tumor in some patients with advanced cancer. In these trials LAK cells were activated in medium containing 2{\%} human type A or AB serum. We have found three commercially available, serum-free culture media which allow development of in vitro LAK activity by human peripheral blood lymphocytes. They are AIMV (Gibco), MASF-3 (Whitaker-MA Bioproducts) and HB-104 (Dupont). If 2-mercaptoethanol was added to these culture media they were also capable of generating murine LAK cells which were effective in reducing pulmonary metastases in the murine MCA-106 model. Although LAK cells generated in these media have not been tested in humans yet, potentially they could provide a safe, unlimited and less expensive source of culture fluid for generating the large numbers of LAK cells needed for human clinical trials.",
keywords = "Immunotherapy, adoptive, Interleukin-2, recombinant, Lymphokine-activated killer cell, Serum-free culture medium",
author = "{Mesler Muul}, Linda and Kathryn Nason-Burchenal and Cornelia Hyatt and Susan Schwarz and Dale Slavin and Director, {Elaine P.} and Rosenberg, {Steven A.}",
year = "1987",
month = "12",
day = "24",
doi = "10.1016/0022-1759(87)90265-1",
language = "English (US)",
volume = "105",
pages = "183--192",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Studies of serum-free culture medium in the generation of lymphokine activated killer cells

AU - Mesler Muul, Linda

AU - Nason-Burchenal, Kathryn

AU - Hyatt, Cornelia

AU - Schwarz, Susan

AU - Slavin, Dale

AU - Director, Elaine P.

AU - Rosenberg, Steven A.

PY - 1987/12/24

Y1 - 1987/12/24

N2 - Lymphokine activated killer (LAK) cells administered in conjunction with recombinant interleukin-2 can mediate the regression of metastatic tumor in some patients with advanced cancer. In these trials LAK cells were activated in medium containing 2% human type A or AB serum. We have found three commercially available, serum-free culture media which allow development of in vitro LAK activity by human peripheral blood lymphocytes. They are AIMV (Gibco), MASF-3 (Whitaker-MA Bioproducts) and HB-104 (Dupont). If 2-mercaptoethanol was added to these culture media they were also capable of generating murine LAK cells which were effective in reducing pulmonary metastases in the murine MCA-106 model. Although LAK cells generated in these media have not been tested in humans yet, potentially they could provide a safe, unlimited and less expensive source of culture fluid for generating the large numbers of LAK cells needed for human clinical trials.

AB - Lymphokine activated killer (LAK) cells administered in conjunction with recombinant interleukin-2 can mediate the regression of metastatic tumor in some patients with advanced cancer. In these trials LAK cells were activated in medium containing 2% human type A or AB serum. We have found three commercially available, serum-free culture media which allow development of in vitro LAK activity by human peripheral blood lymphocytes. They are AIMV (Gibco), MASF-3 (Whitaker-MA Bioproducts) and HB-104 (Dupont). If 2-mercaptoethanol was added to these culture media they were also capable of generating murine LAK cells which were effective in reducing pulmonary metastases in the murine MCA-106 model. Although LAK cells generated in these media have not been tested in humans yet, potentially they could provide a safe, unlimited and less expensive source of culture fluid for generating the large numbers of LAK cells needed for human clinical trials.

KW - Immunotherapy, adoptive

KW - Interleukin-2, recombinant

KW - Lymphokine-activated killer cell

KW - Serum-free culture medium

UR - http://www.scopus.com/inward/record.url?scp=0023572106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023572106&partnerID=8YFLogxK

U2 - 10.1016/0022-1759(87)90265-1

DO - 10.1016/0022-1759(87)90265-1

M3 - Article

C2 - 3693906

AN - SCOPUS:0023572106

VL - 105

SP - 183

EP - 192

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 2

ER -